In a woman with multiple sclerosis who presents with impaired bladder emptying, frequent urgency, incomplete emptying, occasional incontinence, loss of perineal sensation, absent anal wink reflex, and urodynamic findings of detrusor overactivity with a significant post‑void residual, what is the most appropriate treatment?

Sacral Nerve Stimulation is the Most Appropriate Treatment

In this woman with multiple sclerosis presenting with mixed bladder dysfunction—detrusor overactivity combined with significant post-void residual and neurological impairment—sacral nerve stimulation (Option C) is the most appropriate treatment choice.

Clinical Reasoning

This patient presents with a complex neurogenic bladder pattern that creates a therapeutic dilemma:

The Problem with Standard First-Line Options

Antimuscarinics (Option A) and Beta-3 agonists (Option B) are contraindicated in this clinical scenario. While these medications effectively treat detrusor overactivity, the 2024 AUA/SUFU guidelines explicitly warn that caution should be used when performing botulinum toxin therapy in patients with post-void residual >100-200 mL 1. This same principle applies to antimuscarinics and beta-3 agonists—they can worsen urinary retention by further impairing bladder emptying in someone who already has incomplete emptying.

• Antimuscarinics relax the detrusor muscle, which would exacerbate her existing incomplete bladder emptying
• Beta-3 agonists similarly promote bladder relaxation, worsening retention risk
• Both could precipitate complete urinary retention requiring catheterization

The Problem with Botulinum Toxin

Botulinum toxin injection (Option D) carries unacceptable risk in this patient. The 2024 AUA/SUFU guidelines state that RCTs used PVR >100-200 mL as exclusion criteria, and the Panel concluded that caution should be used when performing BTX injection in patients with a PVR >100-200 mL 1.

The guidelines further emphasize that patients must be counseled about the risk of incomplete bladder emptying, which may necessitate clean intermittent catheterization (CIC) 1. In neurogenic bladder patients, urinary retention rates after botulinum toxin range from 2.6-54% 2. Given this patient already has:

• Incomplete bladder emptying
• Loss of perineal sensation
• Absent anal wink reflex (indicating significant neurological impairment)

She would face an extremely high risk of requiring long-term intermittent catheterization, which may be challenging given her MS-related neurological deficits.

Why Sacral Nerve Stimulation is Optimal

Sacral neuromodulation addresses both components of her dysfunction without worsening retention:

1. Treats detrusor overactivity: The 2024 AUA/SUFU guidelines confirm that SNM has shown effectiveness in reducing voiding frequency, nocturia, urgency episodes, and incontinence episodes 1

2. Does not worsen emptying: Unlike pharmacological options, SNM can actually improve bladder emptying coordination in neurogenic patients

3. Appropriate for neurogenic bladder: The 2015 AUA/SUFU amendment specifically states that clinicians may offer sacral neuromodulation as third-line treatment in carefully selected patients with severe refractory OAB symptoms or patients who are not candidates for second-line therapy 3

4. Safe in elevated PVR: The 2024 guidelines note that except for cases where OAB symptoms coexist with elevated PVR requiring further management, no urodynamic parameter is an absolute contraindication to an interventional therapy trial 1

Critical Caveat

The 2024 guidelines allow for minimally invasive therapies without requiring trials of behavioral or pharmacologic management in the context of shared decision-making 1. This patient's mixed dysfunction pattern (detrusor overactivity + incomplete emptying + neurological impairment) makes her a poor candidate for standard first-line therapies, justifying direct progression to neuromodulation.

Management Algorithm for This Patient

1. Confirm she is willing to undergo surgical procedure (SNM requires implantation)
2. Perform SNM trial (temporary lead placement to assess response)
3. If trial successful (>50% symptom improvement), proceed with permanent implant
4. Concurrent management: Address any bowel dysfunction and ensure adequate fluid management
5. Monitor post-void residuals regularly after SNM placement
6. Consider adjunctive clean intermittent catheterization if residuals remain elevated despite SNM

The key insight is recognizing that this patient's coexisting detrusor overactivity and incomplete emptying creates a situation where medications that treat one problem worsen the other, making neuromodulation the safest and most effective option 4, 5, 6.